|
|
Post by itellthefuture777 on Feb 27, 2020 15:28:50 GMT -5
www.businesswire.com/news/home/20180912005155/en/TechnoVax-Awarded-1.5-Million-NIH-Grant-DevelopELMSFORD, N.Y.--(BUSINESS WIRE)--TechnoVax, Inc., a biotechnology developer of novel vaccines has received a two-year $1,481,000 SBIR-II grant from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) to support TechnoVax program to further develop a broadly protective (universal) virus-like particle (VLP) based influenza vaccine utilizing its proprietary and patented VLP technology. Preliminary efficacy studies performed in animals have shown very high levels of cross-reactive protection. “We very much appreciate this NIAID grant which provides strong support to our universal influenza vaccine development program. This award further validates our strategy to create not only a new vaccine able to provide high efficacy, breadth and duration of protection (five or more years) but also a manufacturing system utilizing flexible and controllable cell-based production technologies. This will offer invaluable tools to effectively combat the seasonal and potential pandemic threats persistently imposed by the influenza virus globally,” stated Dr. Jose M. Galarza, CEO of TechnoVax, Inc. Influenza is a major respiratory infectious disease of global reach that affects all demographics and imposes a heavy public health and economic burden. Development of a universal vaccine able to promote immunity that blocks the constantly changing seasonal flu viruses and potentially emerging pandemic strains over time is the most sought outcome to mitigate and even halt the impact of influenza. TechnoVax has been engaged in the mission of creating a universal flu vaccine for many years. TechnoVax’ VLP technology is a novel way to produce vaccines against dangerous viruses as VLPs contain no infectious material and are highly immunogenic. TechnoVax' VLP vaccine technology uses a rapid, safer and more effective cell-based system for development and production, reducing the time and costs of more traditional vaccine production systems. The VLP vaccine technology is one of the most advanced technologies in the vaccine field. TechnoVax is presently evaluating in preclinical phase vaccines to protect against viral infections such as influenza, respiratory syncytial virus, flavivirus and others. About TechnoVax Inc. TechnoVax is a privately held biotechnology company based in Westchester County, NY and specializes in vaccine development using its unique and innovative VLP platform technology. The company is committed to develop safe and highly effective novel vaccines to address significant unmet medical needs of global impact. Learn more at www.technovax.com
|
|
|
|
Post by falconquest on Feb 27, 2020 17:54:16 GMT -5
www.businesswire.com/news/home/20180912005155/en/TechnoVax-Awarded-1.5-Million-NIH-Grant-DevelopELMSFORD, N.Y.--(BUSINESS WIRE)--TechnoVax, Inc., a biotechnology developer of novel vaccines has received a two-year $1,481,000 SBIR-II grant from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) to support TechnoVax program to further develop a broadly protective (universal) virus-like particle (VLP) based influenza vaccine utilizing its proprietary and patented VLP technology. Preliminary efficacy studies performed in animals have shown very high levels of cross-reactive protection. “We very much appreciate this NIAID grant which provides strong support to our universal influenza vaccine development program. This award further validates our strategy to create not only a new vaccine able to provide high efficacy, breadth and duration of protection (five or more years) but also a manufacturing system utilizing flexible and controllable cell-based production technologies. This will offer invaluable tools to effectively combat the seasonal and potential pandemic threats persistently imposed by the influenza virus globally,” stated Dr. Jose M. Galarza, CEO of TechnoVax, Inc. Influenza is a major respiratory infectious disease of global reach that affects all demographics and imposes a heavy public health and economic burden. Development of a universal vaccine able to promote immunity that blocks the constantly changing seasonal flu viruses and potentially emerging pandemic strains over time is the most sought outcome to mitigate and even halt the impact of influenza. TechnoVax has been engaged in the mission of creating a universal flu vaccine for many years. TechnoVax’ VLP technology is a novel way to produce vaccines against dangerous viruses as VLPs contain no infectious material and are highly immunogenic. TechnoVax' VLP vaccine technology uses a rapid, safer and more effective cell-based system for development and production, reducing the time and costs of more traditional vaccine production systems. The VLP vaccine technology is one of the most advanced technologies in the vaccine field. TechnoVax is presently evaluating in preclinical phase vaccines to protect against viral infections such as influenza, respiratory syncytial virus, flavivirus and others. About TechnoVax Inc. TechnoVax is a privately held biotechnology company based in Westchester County, NY and specializes in vaccine development using its unique and innovative VLP platform technology. The company is committed to develop safe and highly effective novel vaccines to address significant unmet medical needs of global impact. Learn more at www.technovax.com Itell,
Good to see you're still hanging around. I like dates on everything (I think anything posted on the web should brandish a date). This article was from September 2018. Let's hope Technovax has a rabbit to pull out of their hat. Here's some info.....
|
|
|
|
Post by itellthefuture777 on Feb 27, 2020 19:00:30 GMT -5
www.businesswire.com/news/home/20180912005155/en/TechnoVax-Awarded-1.5-Million-NIH-Grant-DevelopELMSFORD, N.Y.--(BUSINESS WIRE)--TechnoVax, Inc., a biotechnology developer of novel vaccines has received a two-year $1,481,000 SBIR-II grant from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) to support TechnoVax program to further develop a broadly protective (universal) virus-like particle (VLP) based influenza vaccine utilizing its proprietary and patented VLP technology. Preliminary efficacy studies performed in animals have shown very high levels of cross-reactive protection. “We very much appreciate this NIAID grant which provides strong support to our universal influenza vaccine development program. This award further validates our strategy to create not only a new vaccine able to provide high efficacy, breadth and duration of protection (five or more years) but also a manufacturing system utilizing flexible and controllable cell-based production technologies. This will offer invaluable tools to effectively combat the seasonal and potential pandemic threats persistently imposed by the influenza virus globally,” stated Dr. Jose M. Galarza, CEO of TechnoVax, Inc. Influenza is a major respiratory infectious disease of global reach that affects all demographics and imposes a heavy public health and economic burden. Development of a universal vaccine able to promote immunity that blocks the constantly changing seasonal flu viruses and potentially emerging pandemic strains over time is the most sought outcome to mitigate and even halt the impact of influenza. TechnoVax has been engaged in the mission of creating a universal flu vaccine for many years. TechnoVax’ VLP technology is a novel way to produce vaccines against dangerous viruses as VLPs contain no infectious material and are highly immunogenic. TechnoVax' VLP vaccine technology uses a rapid, safer and more effective cell-based system for development and production, reducing the time and costs of more traditional vaccine production systems. The VLP vaccine technology is one of the most advanced technologies in the vaccine field. TechnoVax is presently evaluating in preclinical phase vaccines to protect against viral infections such as influenza, respiratory syncytial virus, flavivirus and others. About TechnoVax Inc. TechnoVax is a privately held biotechnology company based in Westchester County, NY and specializes in vaccine development using its unique and innovative VLP platform technology. The company is committed to develop safe and highly effective novel vaccines to address significant unmet medical needs of global impact. Learn more at www.technovax.com Itell,
Good to see you're still hanging around. I like dates on everything (I think anything posted on the web should brandish a date). This article was from September 2018. Let's hope Technovax has a rabbit to pull out of their hat. Here's some info.....
Hello Falcon! I like dates on things as well and will see what I can find more recently. I do see some DOD contracts with Technovax...and a 2019 award and some 2019 patents..just haven't pulled them in..will look at those later tonight |
|
|
|
Post by kc on Feb 27, 2020 21:26:58 GMT -5
I still like their graphic illustration of what they are doing. Wouldn’t it be Great if they were part of the solution along with MannKind in a vaccine. Even if experimental.  “Inhaled Powder” technovax.com/inhaled-powder-vaccines/Vaccines “Shelf-Stable, Self-Inhaled, Powderized” VLP Vaccines. TechnoVax and MannKind Corp. have combined their respective technologies to create a Powder Formulation of VLP Influenza Vaccine for Intrapulmonary Self-Delivery by Inhalation. No refrigeration is required, and because it is potentially self-administered public exposure is limited. In the event of an emerging pandemic the vaccine could be easily distributed to the population, greatly reducing the spread of the virus! Advantages Extended Shelf Life and Elimination of Cold Chain results in improved distribution costs and inventory management. Best Route of Immunization (mucosal surface – respiratory tract) Increased Patient Acceptance (inhaled vs. injection) inhaled-powder VLP’s are combined with FPDK Excipient Particles for optimized airflow delivery using the Cricket Inhalation Device. “Inhaled Powder” Vaccines “Shelf-Stable, Self-Inhaled, Powderized” VLP Vaccines. TechnoVax and MannKind Corp. have combined their respective technologies to create a Powder Formulation of VLP Influenza Vaccine for Intrapulmonary Self-Delivery by Inhalation. No refrigeration is required, and because it is potentially self-administered public exposure is limited. In the event of an emerging pandemic the vaccine could be easily distributed to the population, greatly reducing the spread of the virus! Advantages Extended Shelf Life and Elimination of Cold Chain results in improved distribution costs and inventory management. Best Route of Immunization (mucosal surface – respiratory tract) Increased Patient Acceptance (inhaled vs. injection) inhaled-powder VLP’s are combined with FPDK Excipient Particles for optimized airflow delivery using the Cricket Inhalation Device. |
|
|
|
Post by audiomr on Feb 29, 2020 12:46:09 GMT -5
Just for laughs, I went to the Technovax pipeline page, technovax.com/pipeline. Hasn't changed since I first looked at it years ago. Most likely reason Mannkind says nothing about Technovax is that nothing is happening there, and probably nothing will unless Mannkind is prepared to pay for it. We need more partners that have capital to get things done, like UTHR. |
|
|
|
Post by brotherm1 on Feb 29, 2020 13:09:12 GMT -5
If MNKD continues in the direction we appear to be going: thinking about selling off the pipeline except for pulmonary related molecules, not growing Afrezza sales fast enough, struggling for cash, preparing to manufacture trepostinil for UTHR: MNKD might soon be the property of UTHR for a few dollars a share or less.
|
|
|
|
Post by wmdhunt on Mar 1, 2020 12:48:12 GMT -5
Is it just lack of money that keeps MNKD from innovating on vaccines and other blockbuster drugs? The patents apparently are not being exploited or developed further. What good are they if ignored? So disappointed in lack of excitement here.
|
|
|
|
Post by goyocafe on Oct 11, 2020 15:10:19 GMT -5
Just for laughs, I went to the Technovax pipeline page, technovax.com/pipeline. Hasn't changed since I first looked at it years ago. Most likely reason Mannkind says nothing about Technovax is that nothing is happening there, and probably nothing will unless Mannkind is prepared to pay for it. We need more partners that have capital to get things done, like UTHR. Well, sometime between the above post and today Technovax actually updated their pipeline page on the website to include COVID research. www.technovax.com/pipeline-1 |
|
|
|
Post by peppy on Oct 11, 2020 15:25:42 GMT -5
Just for laughs, I went to the Technovax pipeline page, technovax.com/pipeline. Hasn't changed since I first looked at it years ago. Most likely reason Mannkind says nothing about Technovax is that nothing is happening there, and probably nothing will unless Mannkind is prepared to pay for it. We need more partners that have capital to get things done, like UTHR. Well, sometime between the above post and today Technovax actually updated their pipeline page on the website to include COVID research. www.technovax.com/pipeline-1TechnoVax and MannKind Corp. have combined their respective technologies to create a Powder Formulation of VLP Influenza Vaccine for Intrapulmonary Self-Delivery by Inhalation. No refrigeration is required, and because it is potentially self-administered public exposure is limited. In the event of an emerging pandemic the vaccine could be easily distributed to the population, greatly reducing the spread of the virus! Advantages Extended Shelf Life and Elimination of Cold Chain results in improved distribution costs and inventory management. Best Route of Immunization (mucosal surface – respiratory tract) Increased Patient Acceptance (inhaled vs. injection) |
|
|
|
Post by goyocafe on Oct 11, 2020 15:55:34 GMT -5
Well, sometime between the above post and today Technovax actually updated their pipeline page on the website to include COVID research. www.technovax.com/pipeline-1TechnoVax and MannKind Corp. have combined their respective technologies to create a Powder Formulation of VLP Influenza Vaccine for Intrapulmonary Self-Delivery by Inhalation. No refrigeration is required, and because it is potentially self-administered public exposure is limited. In the event of an emerging pandemic the vaccine could be easily distributed to the population, greatly reducing the spread of the virus! Advantages Extended Shelf Life and Elimination of Cold Chain results in improved distribution costs and inventory management. Best Route of Immunization (mucosal surface – respiratory tract) Increased Patient Acceptance (inhaled vs. injection) “Our COVID-19 Vaccine is advancing at high speed and could be ready to enter the clinical Ph. I within a few months if financing is secured.” Only issue is there is no point of reference when this was added to the pipeline page, but Technovax has issued press releases in the past when they have secured funding. |
|
|
|
Post by uvula on Oct 11, 2020 17:20:44 GMT -5
A covid vaccine using a dreamboat that does not require refrigeration would be huge. Mnkd could be a $3 stock!
|
|
|
|
Post by Clement on Oct 11, 2020 17:48:20 GMT -5
|
|
|
|
Post by goyocafe on Oct 11, 2020 18:10:38 GMT -5
It’s a bit of a facetious question, but does MC even know about Technovax and the partnership? Would be well received to get an update on their relationship and progress. |
|
|
|
Post by mnkdfann on Oct 11, 2020 20:58:09 GMT -5
Just for laughs, I went to the Technovax pipeline page, technovax.com/pipeline. Hasn't changed since I first looked at it years ago. Most likely reason Mannkind says nothing about Technovax is that nothing is happening there, and probably nothing will unless Mannkind is prepared to pay for it. We need more partners that have capital to get things done, like UTHR. I agree. In 15+ years (since 2004), what has Technovax achieved? Looks like everything on its site is at the pre-clinical stage at best. Some of these things, it has been been talking about for 10+ years. |
|
|
|
Post by georgethenight2 on Oct 11, 2020 23:06:05 GMT -5
Just for laughs, I went to the Technovax pipeline page, technovax.com/pipeline. Hasn't changed since I first looked at it years ago. Most likely reason Mannkind says nothing about Technovax is that nothing is happening there, and probably nothing will unless Mannkind is prepared to pay for it. We need more partners that have capital to get things done, like UTHR. Same to be said about RLS. Although we recieved $1m nearly 4 years ago, there has been nothing short of a whisper here and a proof of concept presentation there. We are in all likihood many years away from anything happening substantially. And while I, like most here hope for more, the best bet for advancement in my opinion while come from a big player such as $UTHR. If their medicine with our inhaler works, we just might see a cross-branding affect. Users of Trep-T influencing others in the Afrezza sphere and visーversa. |
|
